Adenine nucleoside and nucleotide analogs have been shown to be capable of interfering with deoxyribonucleic acid (DNA) synthesis in bacteria, bacteriophages, mammalian viruses, and cancerous and normal mammalian cells. One substance which has been well studied is 2',3'-dideoxyadenosine (DDA) (5, 8, 10, 12, 13, 17) . Studies with DDA have been carried out primarily by using this substance as a tool to better understand the mechanism(s) by which DNA is synthesized in bacteria (8, 17) , mammalian viruses (1) , and bacteriophages (10, 12) and the effect of other adenosine nucleosides on DNA synthesis in mammalian cells (5, 13) .
No information is available, however, concerning the potential use of DDA as an antibacterial agent. During the course of testing a series of purine nucleosides and nucleotides for antimicrobial activity, it was found that DDA not only possessed in vitro antibacterial activity but surprisingly was also effective in vivo in mouse protection studies against several Salmonella strains at doses well below the toxic level. Because of the in vivo activity, more extensive studies were carried out with DDA and related compounds to: (i) determine the structural specificity required for activity; (ii) investigate the spectrum of antibacterial activity of DDA; and (iii) determine whether a significant inhibition of DNA synthesis occurred only in bacterial strains which were susceptible in vitro or in vivo or both to DDA and, if so, was there a correlation between the inhibition of DNA synthesis and the observed in vitro or in vivo activity or both.
MATERLALS AND METHODS
Chemical agents and antibiotics. DDA, 2',3'-dideoxyinosine, 2',3'-dideoxyguanosine, N,N-dimethyl-2',3'-dideoxyadenosine, 2',3'-dideoxyadenosine-5'-monocarboxymethylphosphonic acid disodium salt (0.7 M hydrate), and 3'-deoxyadenosine (Cordycepin) were prepared in the Chemical Research Department of Hoffmann-La Roche Inc., Nutley, N.J. Adenosine-5'-phosphoric acid, adenosine, guanosine, and inosine were obtained from commercial suppliers. (15) .
Quantitation of inhibition of DNA synthesis. The degree of inhibition of DNA synthesis was quantitated by comparing the rate of DNA synthesis in the bacterial cultures exposed to DDA with that in the controls lacking DDA. The rates were calculated with data from samples taken during the first 20 or 30 min of incubation with the radioactive precursor, since the rate of incorporation was relatively constant up to these times. The inhibitory effect on DNA synthesis could be quantitated with an r value, which is the ratio of the rate of synthesis in the presence of DDA to that in its absence. The r values for all of the strains tested ranged from 0.09 to 0.83, corresponding to a 91 to 17% inhibition of DNA synthesis, respectively.
Correlation of DNA inhibition with DDA concentration. Cultures were grown in TSB or Davis A medium and exposed to different concentrations of DDA. DNA synthesis was monitored and compared with that of the control culture lacking DDA. The r values were calculated at each DDA concentration and plotted against the logarithm of the DDA concentration. The line fitted to each set of points by a leastsquares analysis was then used for estimating the concentration of DDA in micrograms per milliliter which inhibited DNA synthesis by 50% (C50).
In vivo tests. (i) Toxicity. The acute toxicity of DDA was determined in Swiss albino mice weighing 18 to 20 g by administering a single oral, intraperitoneal, or subcutaneous dose. The animals were observed for 72 h, and the 50% lethal dose was calculated by the method of Reed and Muench (14) .
(ii) Systemic infections. All experiments were carried out in Swiss albino mice weighing 18 to 20 g. The animals were infected intraperitoneally with 0.5 ml of appropriate diluted suspensions of overnight cultures containing 100 to 1,000 minimal lethal doses. Infecting inocula for S. pyogenes, S. pneumoniae, and K. pneumoniae A were diluted in TSB. Infecting inocula for all other bacteria were prepared in 5% mucin.
The animals were treated orally or subcutaneously with graded doses of DDA or related substances in 1-ml amounts. Six animals were used for each dosage level, and each experiment in which activity was observed was repeated two or more times. The animals were treated at the following times relative to infection: immediately after infection and 5, 24, 29, 48, and 72 h postinfection.
The total number of mice surviving at each dose for 14 days was used to calculate the 50% protective dose (PD50) by the method of Reed and Muench (14) . The PD50 values, therefore, represent the average of at least three separate experiments.
RESULTS
Acute toxicity. The 50% lethal dose values in mice were 5,000, 1,320, and >500 mg/kg when DDA was administered by the oral, subcutaneous, and intraperitoneal routes, respectively. The acute toxicities of the other DDA-related compounds were not determined because of an insufficient amount of compound.
Cytoxicity. The results of cytoxicity studies (data not shown) with DDA on human amnion cells demonstrated that DDA was tolerated at >-1,000 iLg/Im Structural specificity for in vivo activity. The results of experiments on structural specificity for in vivo activity are shown in Table 1. DDA and 2',3'-dideoxyinosine were active orally.
DDA showed the same effect subcutaneously against the two Salmonella species. 2',3'-Dideoxyguanosine, N,N-dimethyl-2',3'-dideoxyadenosine, 3'-deoxyadenosine (Cordycepin), and 2',3'-dideoxyadenosine-5'-monocarboxymethylphosphonic acid disodium salt were inactive at the highest doses tested by the oral route and also when tested by the subcutaneous route. In addition to these six substances, adenosine-5'-phosphoric acid, adenosine, guanosine, and inosine were evaluated in vivo for oral activity against the two Salmonella species. All substances were inactive at doses ranging from 250 to 1,000 mg/kg.
In vivo and in vitro activities. DDA was found to be orally active (PD50, s250 mg/kg) VOL. 19, 1981 on July 6, 2017 by guest http://aac.asm.org/ With the exception of 3 strains of S. marcescens and 1 strain of E. coli, the 18 strains which responded in vivo had MIC values of 62.5 to 250 ,ug/ml. The MBC values for the 18 strains were equivalent or at most fourfold higher than the MIC values. The one E. coli strain (503-455) had a PD50 value of 42 mg/kg and an MIC value of 500 ,tg/ml in TSB. The three Serratia strains (S966, S303, and S714) all had PD50 values of <150 mg/kg but MIC values of 21,000 ,tg/ml. Of the 37 strains that did not respond to DDA in vivo, the MIC values for 19 strains were 250,ug or less per ml, and the MBC values were equivalent or at most fourfold higher, whereas the MIC and MBC values for the remainder were >250 jig/ml.
Correlation of DNA inhibition with in vitro and in vivo activities. The effects of DDA on protein, RNA, and DNA syntheses were determined for 14 strains selected on the basis of their in vitro and in vivo responses to DDA (Table 2 ). In no case did DDA cause a significant inhibition of protein or RNA synthesis.
As shown in Table 2 , the 14 strains selected could be divided into four general classes on the basis of their in vitro and in vivo susceptibilities to DDA. The organisms susceptible both in vitro and in vivo to DDA (strains A to F) had MIC values in both media ranging from 63 to 125 ,ug/ ml, with the exception of E. coli 503-455, which in TSB had an MIC value of 500 ,ug/ml, and low r225 values (0.10 to 0.29) in both media and, 1, 750 ,ug/ml).
Although the addition of DDA had no apparent effect during the 1-h incubation period on the growth rate of the bacterial cultures as measured by optical density, it had a profound effect on their morphology, causing the formation of long filaments.
Synergy. When DDA was combined in a 1:1 ratio with nalidixic acid, amoxicillin, mecillinam, or gentamicin and tested in vivo against Citrobacter freundii 10 or Shigella flexneri LA, no synergy was observed with any of the combinations (data not shown). DISCUSSION In the testing of a series of adenosine nucleosides and nucleotides for antimicrobial activity, it was shown that DDA not only possessed activity in vitro against a variety of gram-negative bacteria but also was effective in vivo in mouse infections. The spectrum of in vivo activity was not sufficiently broad for DDA to compete with antimicrobial agents such as nalidixic acid, amoxicillin, and gentamicin. However, the doses at which protection was generally observed (i.e., from 12 50% lethal dose (5,000 mg/kg) for the substance when administered orally. The relative nontoxic nature of the substance in mice and in human cell cultures and its intrinsic in vivo antibacterial activity suggested that, by combining DDA with another agent which selectively inhibited DNA synthesis (e.g., nalidixic acid) or protein synthesis (e.g., gentamicin) or with substances which would interfere with cell wall synthesis (e.g., amoxicillin and mecillinam) and so decrease penetration barriers, the activity of DDA in vivo might be broadened. Combinations of DDA with nalidixic acid, gentamicin, amoxicillin, or mecillinam at a ratio of 1:1 were not more effective than the single agents alone against a strain of bacteria susceptible (C. freundii 10) and resistant (S. flexneri LA) to DDA in vivo. Thus, the selective in vivo activity does not appear to be a phenomenon which can be enhanced by the alteration of bacterial cell permeability or metabolic activity. Equally interesting were the highly selective structural requirements for in vivo activity. The natures of both the sugar moiety and the purine base were critical. The introduction of a 2'-hydroxyl group (i.e., 3'-deoxyadenosine) resulted in a loss of activity, as did the introduction of a 5'-phosphonic acid group (2',3'-dideoxyadenosine-5'-monocarboxymethylphosphonic acid disodium salt). The 6-amino group of the adenine moiety does not appear to be crucial for activity, since its replacement with a 6-oxo group (2',3'-dideoxyinosine) did not abolish activity. A possible alternative explanation is the metabolic interconversion of DDA and 2',3'-dideoxyinosine. Further modification of the purine portion (i.e., the addition of an amino group at the 2 position) resulted in an inactive compound (2',3'-dideoxyguanosine). Although the 6-amino group of DDA could be replaced with an oxo group, methylation of this group as in N,N-dimethyl-2',3'-dideoxyadenosine abolished the activity.
From the data presented, it is clear that the Of the possible reasons why DDA is inhibitory to bacteria, but is, unlike most nucleoside analogs (4), not toxic in higher organisms (8, 13) except at high concentrations (6, 11) , two seem to be most important: (i) DDA is rapidly phosphorylated to the active form, the dideoxynucleoside triphosphate, by kinases in bacteria (17) , but only slowly, if at all, by those in animal tissues (3, 13; M. A. Waqar, R. G. Hughes, M. F. Manly, M. J. Evans, and J. A. Huberman, Abstr. Int. Congr. Biochem. 11th, Toronto, Ontario, abstr. no. 01-5-H18, p. 39, 1979), and (ii) there are differences in the intrinsic susceptibility of bacterial and mammalian DNA polymerases to dideoxynucleoside triphosphates. Bacterial polymerases are strongly inhibited by dideoxynucleoside triphosphates (2, 9, 16) , whereas the mammalian polymerases involved in cellular DNA replication are relatively insusceptible (1, 16, 18, 19) .
The results of this study show that DDA is a unique antibacterial agent among nucleoside inhibitors because of its (i) selective toxicity and (ii) limited but definite in vivo activity. It is also of interest that in vitro activity as measured by MIC determinations over an 18-h period correlated well with DNA inhibition measured within a 20-to 30-min time period. ACKNOWLEDGMENTS We thank T. Gabriel of the Chemical Research Department, as well as the Kilo Laboratory, for the synthesis of DDA and the other derivatives described in this paper.
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